⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11825895 | 0.83 | — | — | |
| SCHEMBL28364603 | 0.77 | — | — | |
| SCHEMBL5336374 | 0.77 | — | — | |
| SCHEMBL14352126 | 0.76 | — | — | |
| SCHEMBL6559850 | 0.74 | — | — | |
| SCHEMBL1524919 | 0.69 | — | — | |
| SCHEMBL1524614 | 0.68 | — | — | |
| SCHEMBL17634062 | 0.68 | KDM1A (0.33) | — | |
| SCHEMBL8499286 | 0.66 | — | — | |
| SCHEMBL7202421 | 0.66 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019233579-A1 | ORGANOPOLYSILOXANES THAT CROSS-LINK AT ROOM TEMPERATURE | WACKER CHEMIE AG (DE) | 2019-12-12 | — | — | WO | disclosed |
| EP-3270758-A1 | ADSORPTION OF PARTICLES ON A MATERIAL CONTAINING A SILICON POLYMER | Wacker Chemie AG (DE) | 2018-01-24 | — | — | EP | disclosed |
| WO-2017194099-A1 | ANTIMICROBIAL CROSSLINKED SILICONE POLYMER | WACKER CHEMIE AG (DE) | 2017-11-16 | — | — | WO | disclosed |
| EP-2961424-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | Millennium Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2015107112-A1 | POLYSILOXANES COMPRISING ALPHA-HALOGEN UNITS | WACKER CHEMIE AG (DE) | 2015-07-23 | — | — | WO | disclosed |
| EP-2841103-A1 | DR5 LIGAND DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014134311-A1 | ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2013163229-A1 | DR5 LIGAND DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| EP-2629801-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | Seattle Genetics, Inc. (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-2533804-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | Agensys, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2012054748-A2 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEATTLE GENETICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2011097627-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 161P2F10B PROTEINS | AGENSYS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2038290-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | Gilead Sciences, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005555-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |